Hanwha Pharm seeking injunction trial to invalidate cancellation of product license of Livial

Published: 2003-11-27 07:00:00

Updated: 2003-11-27 07:00:00

Following the Korea Food and Drug Administration's disposition to cancel the product license of Livial on November 22 due to less content of active ingredient in some of bottle products, Hanwha Pharm has recently raised to the Seoul District Court an injunction trial against the KFDA to invalidat...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK